Reported Earlier, Scribe Therapeutics Prices Upsized Initial Public Offering Of 8,580,000 Common Shares At $15.00 Per Share, Expects $128.7M In Gross Proceeds
Share
Why It Matters
Scribe Therapeutics sold shares to the public for the first time, raising about $129 million. When a company does this, it means they have money to spend on their work, so watch if they use it wisely on their main business.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.